INM (InMed Pharma) Company Total Assets

Symbol and logo of brand InMed (INM)

InMed Pharmaceuticals is developing a B2B segment for the synthesis of rare cannabinoids to combat glaucoma and neurodegeneration, aiming to expand its industry presence. The team of biochemists focuses on discovering new therapies for orphan diseases supported by stable financial backing. The historical price action of total assets reflects the value of 10.61. The firm's environmental profile is limited to basic waste utilization and office energy efficiency.

InMed Pharmaceuticals Inc. (INM) Company Total Assets: for the period 07/04/2022 - 10/29/2026

Summary analytical data breakdowns for InMed Pharma (INM)

- price and consensus price forecast:
Share Price inmedpharma.com|INM - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization InMed|INM - Total Company Value
- book capitalization data:
Accounting Value of a Share InMed Pharmaceuticals|INM - Book Capitalization|Market Cap to Net Assets Ratio inmedpharma.com|INM - Aggregate Company Assets
- debt and liquidity data:
Debt to Capital InMed Pharmaceuticals|INM - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital InMed|INM - Company Aggregate Debts|Debts to Book Capitalization Ratio InMed|INM - Company Long-Term Debts|Company Short-Term Debts InMed Pharmaceuticals
Fundamental company analysis:InMed Pharmaceuticals
Core merchandise of InMed

The scale of InMed Pharmaceuticals (INM) operations is reflected in the total asset value, which is reverse-calculated from the return on assets (ROA) to assess the total volume of resources required for diversifying research in dermatology and ophthalmology. Growth in this indicator confirms the expansion of the material base; however, it is critical for investors to correlate this with actual liquidity to avoid hidden imbalances in capital allocation across uncorrelated clinical projects.

Direct competitors

indivior.com (INDV) - Total Business Assets|COLL (Collegium Pharmaceutical, Inc.) - Company Total Assets|Company Total Assets CRON|Tweed (CGC) - Aggregate Company Assets|Aggregate Asset Value Canna Cabana (HITI)|Aurora Cannabis Inc. - Company Total Assets|achievelifesciences.com - Cumulative Company Assets|SKYE (Skye Bioscience) - Aggregate Company Assets|Anebulo Pharmaceuticals Inc (ANEB) - Company Assets|Cumulative Company Assets intercure.co INCR|Nutriband (NTRB) - Aggregate Asset Value|Company Total Assets Nasus Pharma Ltd. NSRX|Total Asset Value of Company IGC Pharma Inc|Company Total Assets MIRA|Company Total Assets FLGC (Flora Growth Corp)|Aggregate Company Assets IM Cannabis|Adial Pharmaceuticals Inc. - Aggregate Asset Value|ARTL: Aggregate Company Assets|ENSC - Cumulative Company Assets|titanpharm.com - Company Total Assets|GNLN (Greenlane Holdings, Inc.) - Company Total Asset Base|Aggregate Company Assets Akanda Corporation (AKAN)|Total Business Assets ENVB|Aggregate Company Assets BGXX (Bright Green)|Cumulative Company Assets Hempacco Co Inc. (HPCO)